Microbiome is as unique as a fingerprint. These bacteria perform important jobs, including maintaining the intestinal barrier ...
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patientsSeres MbTx® platform ...
In a review of nearly 120,000 patients, 31% taking opioids developed C. diff, compared to 17% not taking them Opioids may weaken immunity and disrupt healthy gut bacteria, making infection more likely ...
Fecal microbiota transplant was noninferior to vancomycin as the initial treatment for C. diff in a randomized, open-label trial. Transplant showed slightly higher cure rates without recurrence and ...
SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...
TUESDAY, August 5, 2025 (HealthDay News) — C. diff, which is short for Clostridioides difficile, is a type of bacteria that may cause serious problems in the digestive system. It is one of the most ...
Clinical cure and no disease recurrence within 60 days without additional treatment was observed in 66.7% of 51 patients receiving FMT vs 61.2% of 49 patients receiving vancomycin. HealthDay News — ...
LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and is independent of the L.A. Times ...
Data presented at Digestive Disease Week (DDW) 2025 demonstrated safety and treatment success in patients treated for recurrent C. Diff infection with REBYOTA administered by colonoscopy Data also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback